Hemophilia Market

Mar 2021| MRS113A| Market Research Studies

Report Highlights

The scope of this report covers the different types of Hemophilia, impact of COVID-19 on the market, and therapies used to treat the disorder. The report covers the market value for the historic year 2019, followed by the base year 2020, estimated year 2021 and forecast period from 2020 to 2026 for each type, treatment, therapy, product and regional markets, and the estimated values are derived from the manufacturers’ total revenues.

The report also includes a discussion of the major players across each of the regional Hemophilia markets; it explains the major market drivers of the Global Hemophilia industry, current trends within the industry, major applications and the regional dynamics of the Global Hemophilia Market.

The report concludes with a special focus on the vendor landscape, which includes detailed profiles of the major vendors in the Global Hemophilia Market.

Report Includes

  • 46 tables and 54 figures
  • An up-to-date analysis of the Global Hemophilia Market.
  • Analyses of the global market trends, with data from 2019, 2020, estimates for 2021, and projections of compound annual growth rates (CAGRs) through 2026.
  • Estimation of market size and revenue forecast for Global Hemophilia Market, and corresponding market share analysis by type, treatment, therapy, product, and region.
  • Highlights of emerging technology trends, gaps and opportunities in the market estimating current and future demand for Hemophilia, identification of the companies that are best positioned to meet this demand.
  • In-depth information (facts and figures) concerning market drivers, restraints and other forces affecting the progress of this market.
  • Identification of promising new therapies, and products still in the development and testing stages, and their probability of successful commercial launch within the next five years
  • Impact of COVID-19 on the Hemophilia Market as compared to overall global economy.
  • Insight into the growth development strategies of major Hemophilia manufacturers and their key competitive landscape
  • Descriptive company profiles of the leading market participants, including Octapharma AG, CSL Behring LLC, Pfizer, Inc., Bayer AG, BioMarin Pharmaceutical, Inc., and others.

Summary

Hemophilia, a rare bleeding disorder, is a condition that does not allows the blood to clot normally. Excessive loss of blood could further lead to severe injuries. People diagnosed with hemophilia have reduced levels of either factor IX or factor VIII. There are three types of hemophilia namely, hemophilia A, hemophilia B and hemophilia C. Rising incidences of hemophilia and prophylactic treatment is expected to increase the global hemophilia market. Apart from that various industrial event such as, mergers and acquisitions, new product approvals and launch of new products is going to bolster the Global Hemophilia Market.

The World Health Organization states that the hemophilia disorder is prominent in the males than in females. This disorder usually affects 1 in 5,000 males. Replacement therapy, Immune Tolerance Induction Therapy and Gene therapy are namely three therapies which are used to treat hemophilia.

The Global Hemophilia Market was valued at $11.54 billion in 2020 and is expected to witness a steady growth at a CAGR of 5.8%.

  • Table 1 : Global Hemophilia Market, Through 2026
  • Table 2 : Global Hemophilia Market, by Type, Through 2026
  • Table 3 : Global Hemophilia Market, by Treatment, Through 2026
  • Table 4 : Global Hemophilia Market, by Therapy, Through 2026
  • Table 5 : Global Hemophilia Market, by Product, Through 2026
  • Table 6 : Global Hemophilia Market, by Region, Through 2026
  • Table 7 : North America Hemophilia Market, by Type, Through 2026
  • Table 8 : North America Hemophilia Market, by Treatment, Through 2026
  • Table 9 : North America Hemophilia Market, by Therapy, Through 2026
  • Table 10 : North America Hemophilia Market, by Product, Through 2026
  • Table 11 : North America Hemophilia Market, by Country, Through 2026
  • Table 12 : Europe Hemophilia Market, by Type, Through 2026
  • Table 13 : Europe Hemophilia Market, by Treatment, Through 2026
  • Table 14 : Europe Hemophilia Market, by Therapy, Through 2026
  • Table 15 : Europe Hemophilia Market, by Product, Through 2026
  • Table 16 : Europe Hemophilia Market, by Country, Through 2026
  • Table 17 : Asia-Pacific Hemophilia Market, by Type, Through 2026
  • Table 18 : Asia-Pacific Hemophilia Market, by Treatment, Through 2026
  • Table 19 : Asia-Pacific Hemophilia Market, by Therapy, Through 2026
  • Table 20 : Asia-Pacific Hemophilia Market, by Product, Through 2026
  • Table 21 : Asia-Pacific Hemophilia Market, by Country, Through 2026
  • Table 22 : South America Hemophilia Market, by Type, Through 2026
  • Table 23 : South America Hemophilia Market, by Treatment, Through 2026
  • Table 24 : South America Hemophilia Market, by Therapy, Through 2026
  • Table 25 : South America Hemophilia Market, by Product, Through 2026
  • Table 26 : South America Hemophilia Market, by Country, Through 2026
  • Table 27 : Middle East & Africa Hemophilia Market, by Type, Through 2026
  • Table 28 : Middle East & Africa Hemophilia Market, by Treatment, Through 2026
  • Table 29 : Middle East & Africa Hemophilia Market, by Therapy, Through 2026
  • Table 30 : Middle East & Africa Hemophilia Market, by Product, Through 2026
  • Table 31 : Middle East & Africa Hemophilia Market, by Country, Through 2026
  • Table 32 : Octapharma AG: Financial Performance, Through 2020
  • Table 33 : CSL Behring LLC: Financial Performance, Through 2020
  • Table 34 : Pfizer, Inc.: Financial Performance, Through 2020
  • Table 35 : Bayer AG: Financial Performance, Through 2020
  • Table 36 : BioMarin Pharmaceutical, Inc.: Financial Performance, Through 2020
  • Table 37 : F. Hoffmann-La Roche AG: Financial Performance, Through 2020
  • Table 38 : Novo Nordisk A/S: Financial Performance, Through 2020
  • Table 39 : Sanofi S.A.: Financial Performance, Through 2020
  • Table 40 : Grifols S.A.: Financial Performance, Through 2020
  • Table 41 : Aptevo Therapeutics, Inc.: Financial Performance, Through 2020
  • Table 42 : Sangamo Therapeutics, Inc.: Financial Performance, Through 2020
  • Table 43 : Catalyst Biosciences, Inc.: Financial Performance, Through 2020
  • Table 44 : Takeda Pharmaceutical Company Limited: Financial Performance, Through 2020
  • Table 45 : Baxter International, Inc.: Financial Performance, Through 2020
  • Table 46 : Kedrion S.p.A.: Financial Performance, Through 2020
  • Figure 1 : Global Hemophilia Market
  • Figure 2 : Global Hemophilia Market, by Value, 2019-2026
  • Figure 3 : Global Hemophilia Market, by Value, by Type, 2019-2026
  • Figure 4 : Global Hemophilia Market, by Value, by Treatment, 2019-2026
  • Figure 5 : Global Hemophilia Market, by Value, by Therapy, 2019-2026
  • Figure 6 : Global Hemophilia Market, by Value, by Product, 2019-2026
  • Figure 7 : Global Hemophilia Market, by Value, by Region, 2020
  • Figure 8 : Global Hemophilia Market, by Value, by Company, 2020
  • Figure 9 : Global Hemophilia Market, Product Map, 2020
  • Figure 10 : North America Hemophilia Market, by Value, 2019-2026
  • Figure 11 : North America Hemophilia Market, by Value, by Type, 2019-2026
  • Figure 12 : North America Hemophilia Market, by Value, by Treatment, 2019-2026
  • Figure 13 : North America Hemophilia Market, by Value, by Therapy, 2019-2026
  • Figure 14 : North America Hemophilia Market, by Value, by Product, 2019-2026
  • Figure 15 : North America Hemophilia Market, by Value, by Country, 2020
  • Figure 16 : Europe Hemophilia Market, by Value, 2019-2026
  • Figure 17 : Europe Hemophilia Market, by Value, by Type, 2019-2026
  • Figure 18 : Europe Hemophilia Market, by Value, by Treatment, 2019-2026
  • Figure 19 : Europe Hemophilia Market, by Value, by Therapy, 2019-2026
  • Figure 20 : Europe Hemophilia Market, by Value, by Product, 2019-2026
  • Figure 21 : Europe Hemophilia Market, by Value, by Country, 2020
  • Figure 22 : Asia-Pacific Hemophilia Market, by Value, 2019-2026
  • Figure 23 : Asia-Pacific Hemophilia Market, by Value, by Type, 2019-2026
  • Figure 24 : Asia-Pacific Hemophilia Market, by Value, by Treatment, 2019-2026
  • Figure 25 : Asia-Pacific Hemophilia Market, by Value, by Therapy, 2019-2026
  • Figure 26 : Asia-Pacific Hemophilia Market, by Value, by Product, 2019-2026
  • Figure 27 : Asia-Pacific Hemophilia Market, by Value, by Country, 2020
  • Figure 28 : South America Hemophilia Market, by Value, 2019-2026
  • Figure 29 : South America Hemophilia Market, by Value, by Type, 2019-2026
  • Figure 30 : South America Hemophilia Market, by Value, by Treatment, 2019-2026
  • Figure 31 : South America Hemophilia Market, by Value, by Therapy, 2019-2026
  • Figure 32 : South America Hemophilia Market, by Value, by Product, 2019-2026
  • Figure 33 : South America Hemophilia Market, by Value, by Country, 2020
  • Figure 34 : Middle East & Africa Hemophilia Market, by Value, 2019-2026
  • Figure 35 : Middle East & Africa Hemophilia Market, by Value, by Type, 2019-2026
  • Figure 36 : Middle East & Africa Hemophilia Market, by Value, by Treatment, 2019-2026
  • Figure 37 : Middle East & Africa Hemophilia Market, by Value, by Therapy, 2019-2026
  • Figure 38 : Middle East & Africa Hemophilia Market, by Value, by Product, 2019-2026
  • Figure 39 : Middle East & Africa Hemophilia Market, by Value, by Country, 2020
  • Figure 40 : Octapharma AG: Revenue Share, 2020
  • Figure 41 : CSL Behring LLC: Revenue Share, 2020
  • Figure 42 : Pfizer, Inc.: Revenue Share, 2020
  • Figure 43 : Bayer AG: Revenue Share, 2020
  • Figure 44 : BioMarin Pharmaceutical, Inc.: Revenue Share, 2020
  • Figure 45 : F. Hoffmann-La Roche AG: Revenue Share, 2020
  • Figure 46 : Novo Nordisk A/S: Revenue Share, 2020
  • Figure 47 : Sanofi S.A.: Revenue Share, 2020
  • Figure 48 : Grifols S.A.: Revenue Share, 2020
  • Figure 49 : Aptevo Therapeutics, Inc.: Revenue Share, 2020
  • Figure 50 : Sangamo Therapeutics, Inc.: Revenue Share, 2020
  • Figure 51 : Catalyst Biosciences, Inc.: Revenue Share, 2020
  • Figure 52 : Takeda Pharmaceutical Company Limited: Revenue Share, 2020
  • Figure 53 : Baxter International, Inc.: Revenue Share, 2020
  • Figure 54 : Kedrion S.p.A.: Revenue Share, 2020

Market Research Studies is a North Carolina based, premier market research company. MRS brings over 50 years of market research publishing experience. Our reports cover a variety of industries such as Healthcare, Chemicals, Materials & Manufacturing, Research & Diagnostics, Environment & Sustainability, among others. Each year MRS releases hundreds of reports covering various topics. These reports are prepared by our in-house of team of Industry expert analysts. We strive to provide in-depth market analysis with accurate data to help our customers make informed decisions.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
RELATED REPORTS
Share This Report